Wednesday, 20 Nov 2019

You are here

High Dose Statins Increase Odds of Osteoporosis

It is unknown if inhibiting cholesterol synthesis (with statins) might influence sex-hormone production and therefore, the risk of osteoporosis.  A new study shows that, in statin-treated individuals, the development of osteoporosis is statin dose-dependent. 

This Austrian, claims based study (2006 to 2007) examined the association between statin therapy and OP risk.

The found that in the general population, statin use was associated with a 3 fold higher rate of osteoporosis (OR: 3.62, 95% CI 3.55 to 3.69, p<0.01).

Osteoporosis was significantly lower with low-dose (< 10 mg) statin treatment (e.g., lovastatin [OR: 0.39], pravastatin [OR: 0.68], simvastatin [OR: 0.70] and rosuvastatin [OR: 0.69]; p<0.01).

In contrast, higher doses significantly increased the odds of OP (> 40 mg simvastatin [OR: 1.64]; >20 mg atorvastatin [OR: 1.78]; >20 mg rosuvastatin [OR: 2.04].

It appears that the risk of OP is largely dose-dependent as regards statin use.


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Physical Activity Lowers Fracture Risk in Post-Menopausal Women

An analysis from the Women’s Health Initiative study shows that postmenopausal women who participate in vigorous physical activity have a statistically lower risk of total and site-specific fractures

Sprifermin Benefits Cartilage Loss but not Symptoms in Knee Osteoarthritis

Intra-articular sprifermin given to patients with symptomatic and radiographic knee osteoarthritis has been shown to significantly improve total femorotibial joint cartilage thickness after 2 years, but without significant clinical benefits. Which begs the question, why is there a disconnect between radiographic disease modification (cartilage thickness) and symptomatic improvement?

Bisphosphonates and the Risk of Osteonecrosis of the Jaw

Even though oral bisphosphonates are widely used, there is an inordinate concern over the risk of osteonecrosis of the jaw (ONJ). A new UK study suggests that the risk of ONJ is elevated six fold by the use of biphosphonates.

ASBMR Recommendations on Secondary Fracture Prevention

The American Society for Bone and Mineral Research has developed multistakeholder consensus clinical recommendations for the prevention of secondary fractures for those aged 65 years and older after an initial hip or vertebral fracture.

Overall they have promoted 13 recommendations (7 primary and 6 secondary) strongly supported medical evidence.

Highlights include recommendations for:

Similar Outcomes for Hip Arthroplasty or Hemiarthroplasty in Hip Fracture

The NEJM reports on a randomized comparison of hemiarthroplasty and total hip arthroplasty in displaced femoral neck fractures and shows no difference in function and quality of life over 24 months.